Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats KRAS G12C- mutated mCRC. Sold as Vectibix. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Panitumumab (sold as Vectibix), first approved Sep 27, 2006, with 5 new uses approved and 0 published complete response letters.
First approved: Sep 27, 2006
Applications: 1
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $168M
First approved in the EU: Dec 3, 2007
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
VectibixDrugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent KRAS G12C mutation-positive colorectal cancer that has… · Takeda Pharmaceutical Company Limited · Sep 19, 2025
Clinical Trials
62 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Amgen